GS-III · Science & Tech · GS-IV · Ethics · Biotechnology · India Policy
Bioethics in Biotechnology — Principles, Issues & India's Framework ⚖️
Complete UPSC Notes — What is bioethics, its four core principles (Beauchamp & Childress), bioethical issues across gene editing, genomics, ART/surrogacy, GM crops, organ transplant, animal testing, data privacy, and human experimentation. India's regulatory bodies, landmark cases, ICMR guidelines, current affairs 2024–2026, PYQs, and MCQs.
⚖️ 4 Principles: Autonomy · Beneficence · Non-maleficence · Justice
CRISPR Babies (He Jiankui) — 2018 global scandal
🇮🇳 Genome India Project — 10,000 genomes, Jan 2025
🇮🇳 NexCAR19 — India's first CAR-T therapy, Oct 2023
Surrogacy Act 2021 — commercial ban
ICMR National Ethical Guidelines 2017
📚 Legacy IAS — Civil Services Coaching, Bangalore · Updated: April 2026 · Facts Verified
Section 01 — Foundations
🧭 What is Bioethics? — The Big Picture
💡 The "Traffic Light" Analogy
Science without ethics is like driving without traffic signals — technically powerful but chaotic and dangerous. Bioethics is the traffic signal system for biotechnology: it doesn't stop science from moving, but it governs the speed, direction, and priority given to different vehicles (stakeholders — patients, researchers, companies, society, and future generations). Just as traffic rules balance individual freedom (to drive) with public safety, bioethics balances scientific progress with human dignity, justice, and well-being.
📌 Definition: Bioethics is the branch of applied ethics that examines moral issues arising from advances in biology, medicine, and biotechnology. It addresses questions about what ought to be done — as opposed to what can be done — when science intersects with human life, dignity, and the environment. The word was coined by American biochemist Van Rensselaer Potter in 1970 in his book Bioethics: Bridge to the Future.
📌 Why It Matters for UPSC: Bioethics appears across GS-III (Science & Technology; biotechnology challenges) and GS-IV (Ethics — application of ethical principles to technology, medical ethics). UPSC Mains increasingly asks about ethical dimensions of cutting-edge technologies. Essay topics like "Science without conscience is the ruin of the soul" directly invoke bioethics. Questions on GM crops, gene editing, cloning, surrogacy, animal testing, and data privacy all have bioethical dimensions.
Medical Bioethics
Ethics of clinical practice, patient rights, informed consent, clinical trials, end-of-life decisions, organ transplantation, ART (surrogacy, IVF), gene therapy.
Research Bioethics
Ethics of human and animal experimentation; data privacy in genomics; intellectual property vs. access to medicines; dual-use research (science for both beneficial and harmful use).
Environmental Bioethics
Ethics of GM crops (gene flow, biodiversity loss); biopiracy; patents on life (plant and animal patents); synthetic biology releasing engineered organisms into the environment.
Section 02 — The Core Framework
⚖️ The Four Pillars of Bioethics (Beauchamp & Childress)
📌 Origin: The framework of four principles — often called "Principlism" — was developed by philosophers Tom Beauchamp and James Childress in their book Principles of Biomedical Ethics (1979). It is the most widely used framework in biomedical ethics globally, adopted by WHO, ICMR, and most national regulatory bodies.
1️⃣ Autonomy — Respect for Persons
Every individual has the right to make free, informed decisions about their own body and medical care. Requires informed consent — the patient/participant must be given full information and voluntarily agree. Prohibits coercion, deception, and paternalism.
🔬 Biotech example: In clinical trials of gene therapies or CAR-T cells, patients must be told all risks before enrolling — even when the disease is terminal. India's ICMR guidelines mandate informed consent (with "broad consent" for bio-banking).
⚠️ Violation example: He Jiankui (2018 China) edited embryos without adequate consent procedures; participants reportedly did not fully understand the risks of germline editing.
🌾 Agriculture example: Farmers should be informed about GM seed traits (herbicide tolerance, sterility) before purchasing — not misled by seed companies.
2️⃣ Beneficence — Do Good
Researchers and healthcare providers must act in the best interest of the patient/participant and society. Benefits must outweigh risks. Implies a positive duty to actively promote welfare, not just avoid harm.
🔬 Biotech example: Golden Rice (GM rice with beta-carotene) is developed to address Vitamin A deficiency in developing countries — directly serves beneficence. India's NexCAR19 CAR-T therapy (approved Oct 2023) offers hope to blood cancer patients with no other options.
🌾 Agriculture example: Bt cotton initially reduced farmer pesticide exposure significantly — a genuine benefit. The duty is to ensure such benefits are sustained and equitably distributed.
⚠️ Tension: Beneficence for patients may conflict with beneficence for future generations — e.g., germline gene editing may benefit one individual but alter the human gene pool permanently.
3️⃣ Non-Maleficence — Do No Harm
The oldest principle of medical ethics (primum non nocere — first, do no harm). Requires avoiding unnecessary harm to individuals, communities, or the environment. Closely linked to the Precautionary Principle in environmental ethics.
🔬 Biotech example: CRISPR's off-target effects (unintended gene cuts elsewhere in the genome) represent potential harm. He Jiankui's babies were mosaics — not all cells were edited — and the edited CCR5 deletion may actually increase susceptibility to West Nile and influenza viruses.
🌾 Agriculture example: GM mustard (DMH-11) — the bar gene (herbicide tolerance) raises concerns about gene flow to wild mustard relatives and harm to pollinators (mustard is a key honey bee nectar source). India's Supreme Court stayed commercial release citing harm concerns.
🌍 Environment example: Release of gene-drive organisms (engineered to spread a gene through a wild population) could cause irreversible ecosystem harm — a textbook non-maleficence concern.
4️⃣ Justice — Fair Distribution
Benefits and burdens of biotechnology must be distributed fairly across society. Prohibits exploitation of vulnerable populations. Requires equitable access to medical advances — not just for the rich or powerful. Includes intergenerational justice (obligation to future generations).
🔬 Biotech example: NexCAR19 (India's CAR-T therapy) costs ~₹40 lakh (~$50,000 USD) — 1/10th the US price of $500,000, but still unaffordable for most Indians. Access justice = who benefits from innovation? Only the wealthy?
🌾 Agriculture example: GM seed patents held by Bayer/Monsanto create corporate monopoly — smallholder farmers pay trait fees they can't afford. Contrast with publicly funded GM mustard (DMH-11 by Delhi University), where seeds would theoretically be cheaper.
🧬 Genomics example: Genome India Project — ensuring genomic data benefits Indian communities, not just global pharmaceutical companies. Biotech-PRIDE Guidelines (2021) aim at just data sharing.
⚠️ When Principles Conflict — The Hard Cases for UPSC Mains: The four principles routinely clash with each other. Autonomy vs. Beneficence: A terminal cancer patient wants experimental gene therapy; beneficence demands caution. Non-maleficence vs. Justice: Banning GM crops (non-maleficence for biodiversity) may harm food security of the poor (justice). Autonomy vs. Justice: A surrogate "freely chooses" to be paid — but poverty-driven consent is not truly free (exploitation of vulnerability). These tensions define bioethics debates and are ideal for GS-IV answers.
Section 03 — Issue by Issue
🔬 Major Bioethical Issues in Biotechnology
🧬 A. Human Gene Editing (CRISPR-Cas9)
CRISPR-Cas9 allows precise editing of DNA at specific locations. It can potentially cure inherited diseases (sickle cell, haemophilia, Huntington's), treat cancer, and correct genetic mutations. However, it raises profound ethical questions — especially when applied to germline cells (eggs, sperm, embryos) vs. somatic cells (body cells of a living individual).
| Dimension | Somatic Cell Editing | Germline Cell Editing |
|---|
| What is edited? | Body cells of a living person — change stays in that person | Egg, sperm, or early embryo — change is heritable, passed to all future generations |
| Ethical Status | Broadly accepted with proper consent and safety data (e.g., CAR-T, sickle cell gene therapy) | Highly controversial — crosses the "Rubicon" of human evolution; permanent alteration of the human gene pool |
| Indian Example | NexCAR19 CAR-T (somatic — modifies patient's own T cells, not heritable) | He Jiankui's CRISPR babies (2018) — condemned globally; He sentenced to 3 years in Chinese prison |
| Key Concern | Off-target effects, affordability, access | Off-target effects in embryo; irreversibility; "designer baby" risk; unknown long-term effects on descendants |
| India's Regulation | Regulated by CDSCO (drugs/devices), ICMR guidelines (clinical trials) | No specific legislation; Rules 1989 (EPA) apply to GM organisms including human embryos implicitly |
🗄️ B. Genomics, Data Privacy & Genetic Discrimination
Genomic data is the most personal data — it reveals disease predispositions, ancestral origins, and familial traits. Large-scale genomic projects create unprecedented datasets but also unprecedented risks. Key concerns: (1) Genetic discrimination — employers/insurers using genetic data to deny jobs or coverage (e.g., learning someone has a BRCA1 mutation predisposing to breast cancer); (2) Informed consent complexity — participants may not understand all future uses of their data; (3) Data sovereignty — who owns Indian genomic data? Can pharmaceutical companies patent discoveries made from Indian genomes? (4) Eugenics risk — historical controversies (Nazi Germany's eugenics programme) make genetic databases politically sensitive; (5) Community consent — tribal/indigenous populations have unique concerns about group-level genetic disclosure.
India's response: Biotech-PRIDE Guidelines (2021) — govern ethical sharing of Indian genomic data. Genome India Project data archived at IBDC, Faridabad (India's first national life science data repository). FeED Protocols (Framework for Exchange of Data) launched January 2025 for transparent, fair, responsible data sharing. Data anonymised before public release. Researchers need approval for access — balanced open science with privacy.
👶 C. Assisted Reproductive Technology (ART) & Surrogacy
ART includes IVF, ICSI, gamete donation, embryo cryopreservation, pre-implantation genetic diagnosis (PGD), and surrogacy. Each raises distinct bioethical issues:
IVF & PGD Issues:
• Embryo status: Is a fertilised embryo a person? Surplus embryos from IVF are often discarded or used for research — ethically contested.
• PGD (Pre-implantation Genetic Diagnosis): Screening embryos for genetic diseases before implantation — therapeutic value vs. "designer baby" slippery slope.
• Sex selection: India's PCPNDT Act 1994 bans sex determination — IVF clinics must comply.
• Multi-foetal pregnancy: IVF often implants multiple embryos; selective reduction is ethically complex.
Surrogacy Ethics:
• Commodification of body: Is paying a woman to carry a child treating her as a commodity (Kantian critique — treating persons as means, not ends)?
• Exploitation of poverty: Women from lower-income backgrounds may consent not freely but from economic desperation — is this valid consent?
• Child's rights: The child born has no say; right to know genetic/gestational parentage.
• India's ART Act 2021 + Surrogacy Act 2021: Banned commercial surrogacy; only altruistic surrogacy permitted (close relative, no payment beyond medical expenses). Critics: criminalises women's bodily autonomy; ignores LGBTQ couples.
🌾 D. GM Crops — Agricultural Bioethics
GM crop ethics straddles science, economics, politics, and ecology. Unique features of this domain: (1) Transgenerational & ecological irreversibility — once GM genes spread through pollination, contamination of conventional and organic crops is irreversible; (2) Precautionary Principle (Rio Declaration, Principle 15) — where there are threats of serious or irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing cost-effective measures; (3) Seed sovereignty and farmers' rights — patent-holders can prevent farmers from saving seeds — a justice concern for millions of smallholders; (4) Biopiracy — companies patenting genetic material from traditional crop varieties without benefit-sharing (Neem patent by W.R. Grace was a famous case).
🫀 E. Organ Transplantation & Xenotransplantation
India regulates organ transplantation under the Transplantation of Human Organs and Tissues Act (THOTA), 1994 (amended 2011). Key bioethical issues: organ shortage — India has very low deceased donor rates; organ tourism and trafficking; altruistic vs. paid donation (India prohibits payment to donors); allocation fairness — who gets the organ when there is a shortage? NOTTO (National Organ and Tissue Transplant Organisation) manages the registry. Xenotransplantation — transplanting animal organs (especially pig organs genetically modified to be human-compatible) into humans — raises species-boundary ethics and infection risk (porcine retroviruses). In January 2024, US surgeons performed a second pig kidney transplant into a living human — a major bioethics milestone globally.
Brain death ethics: THOTA defines brain death as legal death — ethically contested; relatives often cannot accept it. Opt-out system (presumed consent for donation) is debated in India — balances organ supply needs against individual autonomy to refuse donation.
🐁 F. Animal Testing & the 3Rs Principle
Biomedical research has long relied on animal testing for drug development, vaccine testing, and surgical training. Ethics framework: The 3Rs — proposed by Russell and Burch (1959): Replace (use non-animal alternatives — cell cultures, computer models, organoids wherever possible), Reduce (minimise numbers used), Refine (minimise pain and distress). India's framework: Prevention of Cruelty to Animals Act 1960; CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals) under MoEF&CC oversees institutional animal ethics committees. India's CDSCO requires animal safety data for drug approval but accepts alternatives where validated. Recent development: US FDA Modernization Act 2022 eliminated the requirement for animal testing before human drug trials — allowing non-animal methods; a global shift with bioethical implications for India's pharmaceutical sector.
Section 04 — Case Studies
📋 Landmark Case Studies — Bioethics in Action
Case 1: He Jiankui CRISPR Babies — 2018 (China)
What happened: In November 2018, Chinese biophysicist He Jiankui at the Southern University of Science and Technology, Shenzhen, announced the birth of twin girls (Lulu and Nana) whose embryonic DNA had been edited using CRISPR-Cas9 to delete the CCR5 receptor gene — the receptor HIV uses to enter white blood cells. His stated goal: make them resistant to HIV infection (their father was HIV-positive). A third gene-edited baby was reportedly born in 2019. He did not obtain proper institutional approval; participants reportedly did not fully understand the risks.
Why it was condemned: (1) Off-target effects — unintended cuts elsewhere in the genome; both twins were mosaics (not all cells edited). (2) CCR5 deletion may increase vulnerability to West Nile virus and influenza. (3) Germline edits are heritable — any children the twins have could inherit the modification. (4) No medical necessity — HIV can be effectively prevented by other means; the risk-benefit ratio was unjustifiable. (5) Consent failure — participants did not fully understand germline editing. (6) Secrecy — conducted without peer review or regulatory clearance.
⚖️ Legal outcome: He Jiankui was sentenced to 3 years in prison and fined 3 million yuan by a Chinese court for "illegal medical practice." China strengthened its ethics governance laws as a direct consequence.
🎓 Bioethics lessons: Science without ethics oversight is catastrophic. Germline editing requires global consensus before any clinical use. The WHO response (2021 Governance Framework) called for an international registry of all human genome editing trials. All four principles were violated: autonomy (inadequate consent), beneficence (unjustifiable risk), non-maleficence (potential harm to twins and descendants), justice (only certain families' children could "benefit").
Case 2: Genome India Project — Privacy vs. Scientific Progress (India, 2020–2025)
What happened: Launched in January 2020 by DBT, coordinated by IISc Bengaluru, involving 20 premier institutions. Completed by January 2025 (announced by PM Modi). Sequenced genomes of 10,000 individuals from 99 distinct population groups. Identified over 55 million genetic variants, many unique to Indian populations. Data archived at IBDC (Indian Biological Data Centre), Faridabad — India's first national life science data repository. FeED Protocols and Biotech-PRIDE Guidelines (2021) govern data sharing.
Bioethical tensions: (1) Informed consent complexity — tribal and indigenous communities may not understand future commercial uses of their genetic data. (2) Data sovereignty — Indian genomic samples historically sent abroad for sequencing; risk of genetic data being commercialised by foreign companies. (3) Genetic discrimination — knowledge of disease-predisposing variants could be used by insurers or employers. (4) Eugenics risk — genetic studies along caste/ethnic lines could reinforce stereotypes or divisive politics. (5) Equity of benefits — will precision medicine developed from Indian genomes be affordable to Indians?
⚖️ Policy response: Data anonymised before release; access requires researcher approval; FeED Protocols ensure fair benefit-sharing; Biotech-PRIDE Guidelines (2021) set ethical standards for Indian biological data. India's DPDP Act 2023 (Digital Personal Data Protection Act) adds a legal layer, though genomic data may need specific supplementary regulation.
🎓 Bioethics lessons: Big data + genomics = big ethical responsibility. Justice demands that those whose DNA is sequenced (often from marginalised communities) share in the medical and economic benefits. Community consent (beyond individual consent) is essential for population-level genomic research.
Case 3: NexCAR19 CAR-T Therapy — Accessibility Ethics (India, 2023)
What happened: NexCAR19 (actalycabtagene autoleucel), developed by ImmunoACT (IIT Bombay spin-off), received CDSCO approval in October 2023 — making it India's first approved CAR-T cell therapy. It genetically engineers a patient's own T cells to target cancer (CD19-positive B-cell malignancies: lymphoma, leukemia). Clinical trials at Tata Memorial Hospital, Mumbai — 67% objective response rate in 53 patients; complete remission in approximately half. Cost: ~₹40 lakh (~$50,000 USD) — 1/10th the US/EU cost of $500,000, but still unaffordable for 95%+ of Indian patients. Available at 30+ hospitals across 10+ cities.
Bioethical tensions: (1) Beneficence — genuine medical breakthrough for patients who have exhausted all other options. (2) Justice — a therapy that costs ₹40 lakh is accessible only to the wealthy; treatment reserved for the few. Raises the question: who owns the benefits of publicly funded biotech innovation? (IIT Bombay is a public university; BIRAC provided initial funding). (3) Informed consent challenge — patients with terminal cancer may be desperate, undermining truly autonomous consent. (4) Side-effect profile — CAR-T can cause severe cytokine release syndrome (CRS) and neurotoxicity — non-maleficence requires rigorous monitoring infrastructure.
⚖️ Status: Government is considering subsidising NexCAR19 under Ayushman Bharat. BIRAC continues to fund next-generation CAR-T research. PM Modi highlighted NexCAR19 at ESTIC 2025 as a flagship Indian innovation.
🎓 Bioethics lessons: Innovation is incomplete without accessibility. Justice principle demands differential pricing, public subsidies, and insurance coverage for life-saving biotech therapies. India's domestic development of an affordable CAR-T is itself an act of bioethical justice — but full justice requires that affordable access reach every cancer patient, not just the privileged.
Case 4: India's Surrogacy (Regulation) Act, 2021 — Autonomy vs. Exploitation
What happened: India was once the world's largest commercial surrogacy hub — a $400-million-a-year industry. Regulation was absent for decades, leading to documented exploitation: women from poor rural backgrounds were housed in dormitories, subject to multiple embryo transfers, and paid modest sums for carrying children for wealthy foreigners. The Surrogacy (Regulation) Act 2021 and ART (Regulation) Act 2021 (both came into force in 2022) banned commercial surrogacy completely. Only altruistic surrogacy is permitted — restricted to close relatives, no payment beyond medical expenses and 36-month insurance, only for married Indian heterosexual couples or widowed/divorced women (aged 35–45).
Bioethical tensions: (1) Autonomy vs. Paternalism: Does the ban protect women from exploitation, or does it deny them the right to make an economic choice about their own bodies? (2) Excluding LGBTQ+ couples violates justice — denying them reproductive options available to heterosexual couples. (3) Altruistic model problems: Pressure on relatives (usually sisters-in-law or cousins) to "volunteer" out of social obligation — is this truly free consent? (4) Post-ban shift: Commercial surrogacy has not disappeared — it has moved underground or across borders (to Georgia, Ukraine, Colombia), making it less regulated and more exploitative.
⚖️ Legal landscape: Several PILs challenging the exclusion of LGBTQ+ couples and single unmarried individuals are pending in courts. Supreme Court directed government to formulate a "no-fault" compensation scheme for cases where surrogacy goes wrong. The 2024 amendment extended eligibility for some categories of single individuals.
🎓 Bioethics lessons: Regulatory bans can solve one ethical problem (exploitation) while creating others (denial of autonomy, exclusion of minorities, driving practices underground). Bioethics demands nuanced regulation — not blanket prohibition — that centres both the surrogate's and the intended parent's dignity.
Section 05 — India's Architecture
🇮🇳 India's Bioethics Regulatory Framework
| Body / Law | Role | Domain |
|---|
| ICMR — Indian Council of Medical Research |
Apex body for biomedical research ethics. Published National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017 (3rd revision). ICMR Bioethics Unit at NCDIR, Bengaluru. Oversees Institutional Ethics Committees (IECs). |
Human research, clinical trials, genomics, ART |
| CDSCO — Central Drugs Standard Control Organisation |
Regulates drugs, clinical trials, medical devices, biologics. Under MoH&FW. Approved NexCAR19 (Oct 2023). Regulates New Drugs & Clinical Trials Rules 2019. |
Drug trials, gene therapies, CAR-T, diagnostics |
| GEAC — Genetic Engineering Appraisal Committee |
Apex body for GM organism approval under EPA Rules 1989. Under MoEF&CC. Approves/rejects GM crop field trials and commercial release. Approved Bt cotton (2002), Bt brinjal (2009, under moratorium), GM mustard DMH-11 (2022, SC stay). |
GM crops, GM organisms, environmental biosafety |
| RCGM — Review Committee on Genetic Manipulation |
Under DBT. Oversees contained research and early-stage biosafety trials (BRL-I, BRL-II). Upstream of GEAC. |
GM crop research, gene therapy early trials |
| CPCSEA |
Committee for the Purpose of Control and Supervision of Experiments on Animals. Under MoEF&CC. Regulates animal experimentation, oversees Institutional Animal Ethics Committees (IAECs). Implements 3Rs principle. |
Animal testing, biomedical animal research |
| National Bioethics Committee (proposed) |
India does not yet have a standalone National Bioethics Committee. Several expert committees, including ICMR groups and SC-appointed panels (e.g., TEC for GMOs), have played the role. A unified committee has been recommended by experts and bioethics advocates. |
Cross-cutting ethics oversight |
| THOTA 1994 (Transplantation of Human Organs & Tissues Act) |
Regulates organ donation and transplant. Defines brain death. Prohibits organ trade. NOTTO (National Organ and Tissue Transplant Organisation) manages registry and allocation. SOTTO (State) and ROTTO (Regional) at lower levels. |
Organ transplant ethics |
| Surrogacy (Regulation) Act 2021 + ART (Regulation) Act 2021 |
Bans commercial surrogacy; permits only altruistic surrogacy (close relative, no payment). National & State Surrogacy Boards created. ART clinics regulated. Criminalises exploitation. Eligibility: married Indian heterosexual couples & widowed/divorced women (35–45). |
ART, IVF, surrogacy, reproductive ethics |
| DPDP Act 2023 (Digital Personal Data Protection Act) |
India's data privacy law — relevant to genomic data protection. Data fiduciaries (including hospitals, genomics companies) must protect personal data. Specific supplementary rules for genomic/health data under development. |
Genomic data privacy, bioinformatics ethics |
| Biotech-PRIDE Guidelines 2021 |
Policies and Regulations for Inclusive, Defined & Efficient sharing of biological data. Launched by DBT. Govern ethical, secure sharing of India's biological datasets including Genome India data. Foundation for FeED Protocols (2025). |
Genomic data sharing ethics |
| PCPNDT Act 1994 |
Pre-Conception and Pre-Natal Diagnostic Techniques Act. Prohibits sex determination of foetus and sex-selective abortion. Bans misuse of genetic/ultrasound technologies for this purpose. Directly intersects with ART and PGD ethics. |
Reproductive genetics, sex selection |
| Patents Act 1970 (amended 2005) — Section 3(b) & 3(j) |
Section 3(b): Prohibits patents on inventions whose primary use would be "contrary to public order or morality." Section 3(j): Prohibits patents on "plants and animals in whole or any part thereof other than micro-organisms." Limits biopiracy; balances IP with ethics and access to genetic resources. |
Biopiracy, GM crop patents, access to medicines |
📌 International Bioethics Instruments (for UPSC context):
• Nuremberg Code (1947): Born from Nazi experiments — 10 principles of human experimentation ethics; voluntary consent is absolute foundation.
• Declaration of Helsinki (1964, revised 2013): World Medical Association; ethical principles for medical research involving human subjects. Foundational for ICMR guidelines.
• Belmont Report (1979): US-origin; established three principles — respect for persons, beneficence, justice (precursor to the four-principle framework).
• UNESCO Universal Declaration on the Human Genome and Human Rights (1997): Human genome is "heritage of humanity"; prohibits reproductive cloning of humans.
• CBD & Nagoya Protocol (2010): Access and Benefit Sharing (ABS) for genetic resources — prevents biopiracy; India is a signatory.
• WHO Governance Framework on Human Genome Editing (2021): Global framework with 9 recommendations — international registry of genome editing trials, prohibition of unsafe/illegal research, equitable access.
• Cartagena Protocol on Biosafety (2000): Regulates transboundary movement of LMOs (Living Modified Organisms — GM crops); India is a party.
Section 06 — Current Affairs
📰 Current Affairs 2024–2026 (Fact-Verified)
🗞️ High-Priority Bioethics News Items for UPSC 2026
JANUARY 2025 — GENOME INDIA
Genome India Project Completed — 10,000 Genomes Unveiled: PM Modi announced completion of the Genome India Project at the Genome India Data Conclave, Vigyan Bhavan, New Delhi (January 9, 2025). The project — launched in January 2020 by DBT, coordinated by IISc Bengaluru, involving 20 institutions — sequenced the complete genomes of
10,000 individuals from 99 distinct population groups. Over
55 million genetic variants identified, many unique to India. Data archived at
IBDC, Faridabad.
FeED Protocols (Framework for Exchange of Data under Biotech-PRIDE Guidelines 2021) launched for ethical, transparent data sharing.
Bioethics angle: informed consent, data sovereignty, genetic discrimination, equitable access to precision medicine benefits.
OCTOBER 2023 / ONGOING 2025 — CAR-T THERAPY
NexCAR19 — India's First CAR-T Cell Therapy, Highlighted at ESTIC 2025: CDSCO approved NexCAR19 (actalycabtagene autoleucel) in
October 2023 — India's first indigenous CAR-T cell therapy, developed by
ImmunoACT (IIT Bombay spin-off) with clinical trials at Tata Memorial Hospital. 67% objective response, ~50% complete remission in 53 patients with B-cell lymphoma/leukemia. Cost: ~
₹40 lakh (~$50,000) vs. ~$500,000 in the US. PM Modi highlighted NexCAR19 as a top-3 Indian innovation at ESTIC 2025. Available at 30+ hospitals across 10+ cities.
Bioethics angle: access justice, pricing ethics, consent in terminal illness, cytokine release syndrome safety monitoring.
2024 — SICKLE CELL GENE THERAPY GLOBAL
First CRISPR-Based Gene Therapy Approved (USA) — India Implications: In December 2023, the US FDA approved
Casgevy (exa-cel) — the world's first CRISPR-based medicine — developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle cell disease and beta-thalassaemia. This is a somatic cell gene therapy (not germline).
India relevance: India has one of the world's highest burdens of sickle cell disease (especially tribal populations in Odisha, Madhya Pradesh, Chhattisgarh). National Sickle Cell Anaemia Elimination Mission launched by India in 2023 with a target to eliminate it by 2047. CRISPR-based cure raises acute access justice questions — Casgevy costs $2.2 million per patient in the US.
Bioethics angle: access to life-saving CRISPR therapies in LMIC; role of public funding in making gene therapies affordable; India's role as a potential manufacturer.
2024 — PIG KIDNEY TRANSPLANT
World's First Genetically Modified Pig Kidney Transplanted into a Living Human (USA, 2024): In March 2024, surgeons at Massachusetts General Hospital transplanted a
genetically modified pig kidney (10 genes modified — 4 pig genes removed, 6 human genes inserted) into a living patient. This xenotransplantation milestone raises bioethical issues: risk of porcine viruses (PERVs — porcine endogenous retroviruses) crossing species; animal rights (use of GM pigs as organ factories); allocation justice (who gets priority for xenotransplants?); long-term safety unknown.
India relevance: THOTA does not address xenotransplantation; India's low deceased donor rates make xenotransplant a potential future solution for organ shortage.
JULY 2024 — GM MUSTARD (INDIA SC)
Supreme Court Split Verdict on GM Mustard DMH-11 — Environmental Bioethics: A two-judge bench delivered a split verdict in July 2024: Justice BV Nagarathna quashed GEAC's October 2022 approval; Justice Sanjay Karol upheld it. Referred to larger bench. Commercial cultivation on hold. At the heart of the case is the
Precautionary Principle — should India allow a GM food crop when India is the centre of mustard biodiversity and long-term safety data is incomplete? This is a pure bioethics case: non-maleficence (gene flow to wild species, pollinator harm, herbicide overuse) vs. beneficence (reduced edible oil imports, food security).
UPSC mains angle: role of judiciary in technology governance; precautionary principle as a bioethics/environmental ethics tool.
2025 — HE JIANKUI COMEBACK CONDEMNED
He Jiankui's Research Comeback Condemned by Global Scientific Community: After completing his 3-year prison sentence in China, He Jiankui attempted to re-enter scientific research (reportedly on DMD — Duchenne Muscular Dystrophy gene therapy). In March 2023, the Chinese academic community — including co-authors of a consensus statement — firmly condemned his return, calling his attitude "irresponsible" and his remarks "misleading." The CRISPR babies scandal has triggered China's comprehensive legal reforms on science and technology ethics governance, including the
Regulation on Science and Technology Ethics Review (2023) requiring institutional ethics review for all risky biotech research.
India relevance: highlights need for India's own comprehensive bioethics legislation, not just piecemeal guidelines.
JANUARY 2024 — TAILOR-MADE GENE THERAPY (USA)
World's First Bespoke (Personalised) Gene Therapy for a Child — New Bioethics Frontier: In May 2025, US scientists reported the world's first successful tailor-made (individualised) gene therapy for a baby born with a rare metabolic disorder (CPS1 deficiency). The therapy was designed specifically for that child's unique mutation — representing a new era of "n-of-1" medicine. Ethically: who has access to therapies costing millions? Is it ethical to invest enormous resources in one-patient therapies when millions lack basic healthcare? This raises the justice principle at the sharpest edge — the individual vs. the collective claim on medical resources.
BUDGET 2025-26 — INDIA BIOTECH
India's Bioeconomy: USD 165.7 billion (2024); Target USD 300 billion by 2030: DBT's Year-End Review 2025 confirmed India's biotech sector grew from USD 10 billion (2014) to USD
165.7 billion (2024), with a USD 300 billion target by 2030. India is now the
world's 12th largest biotech hub, 3rd largest in Asia-Pacific, 3rd largest startup ecosystem globally, and largest vaccine manufacturer. Budget 2025-26 announced a second National Gene Bank (10 lakh germplasm lines). This rapid growth makes robust bioethics governance more urgent — the faster biotechnology grows, the more important ethical guardrails become.
UPSC angle: India's bioeconomy aspiration must be matched with ethical governance infrastructure.
Section 07 — PYQs
📜 Previous Year Questions (PYQs)
🎯 UPSC PYQs — Bioethics & Biotechnology
Mains 2015 (GS-IV)
"Discuss the ethical issues involved in the following: (a) Human cloning (b) Surrogacy (c) Euthanasia."
Key points for (b) Surrogacy: Commodification of body (Kantian ethics); exploitation of economically vulnerable women (justice); child's right to know parentage; autonomy of surrogate; India's Surrogacy Act 2021 banned commercial surrogacy; only altruistic permitted; LGBTQ exclusion raises justice concerns. For (a) Human cloning: reproductive vs. therapeutic cloning; dignity of human life; slippery slope to eugenics; UNESCO 1997 Declaration prohibits reproductive cloning. For (c) Euthanasia: active vs. passive; India's SC judgement in Common Cause vs. Union of India (2018) — allowed passive euthanasia (withdrawal of life support) and "living wills."
Mains 2016 (GS-III)
"What are the ethical issues involved in the practice of surrogate motherhood in India?"
Key points: Autonomy (is consent truly free given economic desperation?); commodification of women's bodies; exploitation of poor women; child's welfare and identity rights; regulation failure before 2021 Act; commercial surrogacy exploitation cases; comparison with altruistic systems in other countries; India's shift to Surrogacy Act 2021 — evaluate whether it truly protects women or merely criminalises their economic choices.
Mains 2019 (GS-III)
"What are the ethical implications of the use of gene-editing technologies like CRISPR? Discuss with reference to India."
Key points: CRISPR mechanism briefly; somatic vs. germline editing distinction (critical); He Jiankui case (2018) as cautionary tale; autonomy (consent for embryo editing — embryo cannot consent); non-maleficence (off-target effects, mosaicism, unknown long-term effects); justice (designer babies = only for the wealthy; genomic inequality); beneficence (cure for sickle cell, thalassaemia — India-specific diseases); India's regulatory gap — EPA Rules 1989 are not designed for human gene editing; need for dedicated legislation; WHO 2021 Governance Framework; position of Indian academic community.
Mains 2020 (GS-III)
"There is an increasing clamour for 'access to genetic resources' and 'equitable sharing of benefits' arising from the utilisation of genetic resources. What do you understand by these terms? Discuss the Nagoya Protocol."
Key points: Genetic resources = living organisms, traditional knowledge associated with them; CBD's three objectives: conservation, sustainable use, fair ABS; biopiracy (Neem case: W.R. Grace patent challenged and revoked; Turmeric patent by US researchers — challenged and revoked); Nagoya Protocol (2010) on ABS — India ratified 2014; India's Biological Diversity Act 2002 and ABS Rules 2014; National Biodiversity Authority (NBA) implements ABS; IBDC and Biotech-PRIDE connect to these concerns for digital sequence information.
Mains 2023 (GS-III)
"Discuss the ethical concerns associated with the use of Artificial Intelligence and biotechnology in healthcare."
Key points: AI + biotech overlap in diagnostics (AI-driven genomic analysis), drug discovery (AlphaFold for protein structure), personalised medicine. Ethical concerns: (1) Algorithmic bias — AI trained on non-Indian data may perform poorly for Indian patients; (2) Privacy — AI processing genomic and health data creates surveillance risks; (3) Accountability — when AI makes wrong diagnosis, who is liable? (4) Access — AI healthcare tools may widen urban-rural, rich-poor divide; (5) Dehumanisation — doctor-patient relationship eroded when AI mediates care; (6) Informed consent — patients may not understand AI's role in their treatment. India's DPDP Act 2023 and National Digital Health Mission (NDHM) are relevant policy touchpoints.
Essay Topics (Related)
Essay themes where bioethics is directly relevant:
• "Science without conscience is the ruin of the soul" (Rabelais)
• "Can technology alone solve the problems of humanity?"
• "Ethics is knowing the difference between what you have a right to do and what is right to do"
• "With great power comes great responsibility" — particularly apt for CRISPR and genomic technologies
Strategy: Use bioethics as a concrete domain to illustrate abstract ethical principles. Case studies (He Jiankui, Genome India, NexCAR19) add depth and specificity.
Section 08 — Practice
📝 UPSC-Style MCQs — Test Yourself
Q1The four principles of biomedical ethics (Beauchamp and Childress) include all of the following EXCEPT:
a) Autonomy
b) Beneficence
c) Sustainability
d) Non-maleficence
The four principles (from Beauchamp & Childress, Principles of Biomedical Ethics, 1979) are: Autonomy, Beneficence, Non-maleficence, and Justice. Sustainability is NOT one of them — it is a principle of environmental/development ethics (Brundtland Commission, 1987), not biomedical ethics. A common distractor in UPSC-style questions. Answer: (c).
Q2Consider these statements about He Jiankui's CRISPR experiment (2018):
1. He edited embryonic genes to delete the CCR5 receptor, aiming to confer HIV resistance.
2. He was awarded the Nobel Prize in Physiology or Medicine for his pioneering work.
3. He was sentenced to 3 years in prison by a Chinese court for illegal medical practice.
4. The experiment involved somatic cell editing — the edits are not heritable.
Which statements are correct?
a) 1 and 2 only
b) 1 and 3 only
c) 2 and 4 only
d) 1, 3 and 4
Statement 1 ✓ — He edited embryos to delete CCR5, through which HIV enters white blood cells. Statement 2 ✗ — He was universally condemned, NOT awarded the Nobel. The 2020 Nobel for CRISPR went to Jennifer Doudna and Emmanuelle Charpentier for the discovery/development of CRISPR tool, not He Jiankui. Statement 3 ✓ — He was sentenced to 3 years in prison and fined 3 million yuan. Statement 4 ✗ — He edited germline cells (embryos), NOT somatic cells. Germline edits are heritable — the modification can be passed to future generations. This is exactly what made the experiment so alarming. Answer: (b).
Q3Which of the following correctly describes the Genome India Project?
a) It was launched in 2025 by ICAR to map the genetic diversity of Indian crop varieties
b) It sequenced the genomes of 1,00,000 individuals from all districts of India
c) It was launched in 2020 by DBT, coordinated by IISc Bengaluru, and sequenced 10,000 genomes from 99 distinct population groups
d) It is a project under CSIR to develop personalised cancer treatments for Indian patients
The Genome India Project was launched in January 2020 by the Department of Biotechnology (DBT), coordinated by the Indian Institute of Science (IISc), Bengaluru, involving 20 premier institutions. It sequenced the genomes of 10,000 individuals from 99 distinct population groups. Completed by January 2025. Data archived at IBDC, Faridabad. Not ICAR (which does crop genetics). Not 1 lakh individuals. Not CSIR (which does industrial/drug research). Answer: (c).
Q4With reference to India's Surrogacy (Regulation) Act, 2021, which of the following statements is correct?
a) It allows commercial surrogacy for Indian citizens but bans it for foreign nationals
b) It bans commercial surrogacy entirely and permits only altruistic surrogacy by a close relative of the intended couple
c) It permits commercial surrogacy with government-regulated payment to the surrogate
d) It was struck down by the Supreme Court in 2024 as unconstitutional
The Surrogacy (Regulation) Act 2021 bans commercial surrogacy entirely — for all persons, Indian or foreign. Only altruistic surrogacy is permitted, where the surrogate is a close relative of the intended couple and receives no monetary compensation beyond medical expenses and 36-month insurance. It has NOT been struck down (as of April 2026) — multiple PILs are pending but the Act remains in force. The Act actually came into force in January 2022. Answer: (b).
Q5The "3Rs" framework in the context of animal testing in biomedical research stands for:
a) Rights, Regulations, and Responsibility
b) Replace, Reduce, and Refine
c) Research, Review, and Reject
d) Register, Report, and Regulate
The 3Rs framework was proposed by William Russell and Rex Burch in their 1959 book The Principles of Humane Experimental Technique: Replace (use non-animal alternatives — cell cultures, computer models, organoids — wherever possible); Reduce (minimise the number of animals used); Refine (modify procedures to minimise pain, distress, and suffering). India's CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals) implements the 3Rs principle. Answer: (b).
Q6NexCAR19, approved by CDSCO in October 2023, is significant because:
a) It is India's first approved CRISPR-based gene therapy for sickle cell disease
b) It is the world's first CAR-T cell therapy, developed by AIIMS New Delhi
c) It is India's first indigenous CAR-T cell therapy, developed by ImmunoACT (IIT Bombay spin-off), for B-cell blood cancers
d) It is India's first approved monoclonal antibody therapy for COVID-19
NexCAR19 is India's first CAR-T (Chimeric Antigen Receptor T-cell) cell therapy — not CRISPR, not monoclonal antibody. Developed by ImmunoACT, a spin-off company of IIT Bombay (not AIIMS). Clinical trials were conducted at Tata Memorial Hospital, Mumbai. It targets CD19-positive B-cell malignancies (lymphoma and leukemia). CRISPR-based therapies are different — Casgevy (for sickle cell) was FDA-approved in December 2023 but is US-developed, not Indian. Answer: (c).
Q7The Precautionary Principle in bioethics/environmental ethics implies that:
a) All new technologies must be proven safe before they are even researched in laboratories
b) Where there is risk of serious or irreversible harm, lack of full scientific certainty is not a reason to postpone protective measures
c) Scientists must always choose the most cautious research path, even if it slows medical progress significantly
d) New biotechnology applications should be banned until 100% safety is established
The Precautionary Principle (Rio Declaration 1992, Principle 15; also in Cartagena Protocol; TFEU Article 191 in EU) states: "Where there are threats of serious or irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing cost-effective measures to prevent environmental degradation." It does NOT require banning research or demand 100% proof of safety — that would halt all science. It sets a proportionate standard: the threshold for action should match the magnitude and irreversibility of the threatened harm. India's Supreme Court has invoked the Precautionary Principle in GM crop cases (GM mustard, Bt brinjal). Answer: (b).
Section 09
🧠 Memory Aid — Lock These In
🔑 Bioethics in Biotechnology — Prelims + Mains Essentials
4 PRINCIPLES
A-B-N-J: Autonomy (informed consent, no coercion) · Beneficence (do good, act in patient's interest) · Non-maleficence (do no harm, precautionary) · Justice (fair access, no exploitation). By Beauchamp & Childress, 1979.
CRISPR BABIES
He Jiankui (China, Nov 2018) — deleted CCR5 gene in embryos (germline — heritable!) for HIV resistance. Result: mosaics, possibly more vulnerable to other viruses. Sentenced to 3 years prison. 2020 Nobel (CRISPR) went to Doudna & Charpentier — NOT He Jiankui.
SOMATIC vs. GERMLINE
Somatic = body cells, not heritable, broadly accepted (e.g., NexCAR19, sickle cell gene therapy). Germline = egg/sperm/embryo, heritable across generations, globally condemned for clinical use. Key distinction for UPSC.
GENOME INDIA
Launched Jan 2020 by DBT, coordinated by IISc Bengaluru, 20 institutions. 10,000 genomes, 99 population groups. Completed Jan 2025 (PM Modi). Data at IBDC, Faridabad. FeED Protocols (2025) for sharing. Biotech-PRIDE Guidelines (2021).
NexCAR19
India's first CAR-T therapy. ImmunoACT (IIT Bombay spin-off). CDSCO approval Oct 2023. B-cell cancers (lymphoma/leukemia). Cost ~₹40 lakh vs. $500K in US. 67% objective response. NOT CRISPR — it modifies T cells (somatic, not germline).
SURROGACY
Surrogacy (Regulation) Act 2021 — bans commercial surrogacy; only altruistic (close relative). ART Act 2021 — regulates IVF clinics. Ethical tension: autonomy of surrogate vs. exploitation of poverty. Excludes LGBTQ couples — justice concern.
ICMR
ICMR = apex body for biomedical research ethics in India. National Ethical Guidelines 2017 (3rd revision). ICMR Bioethics Unit at NCDIR, Bengaluru. Based on Declaration of Helsinki and Belmont Report principles.
ORGAN
THOTA 1994 (Transplantation of Human Organs and Tissues Act) — defines brain death, prohibits organ trade. NOTTO manages registry. Xenotransplantation (pig kidney to human, 2024 USA) — emerging bioethics frontier NOT yet regulated in India.
3Rs
Animal testing ethics — Russell & Burch (1959): Replace (use alternatives), Reduce (minimise numbers), Refine (minimise pain). Implemented by CPCSEA in India (under MoEF&CC).
INTL INSTRUMENTS
Nuremberg Code (1947) → Declaration of Helsinki (1964) → Belmont Report (1979) → UNESCO Genome Declaration (1997) → Cartagena Protocol (2000, biosafety) → Nagoya Protocol (2010, ABS) → WHO Genome Editing Framework (2021).
TRAPS
• Sustainability is NOT a Beauchamp-Childress principle. • He Jiankui = prison (NOT Nobel). • Germline editing = heritable (NOT somatic). • GEAC = under MoEF&CC (NOT DBT). • NexCAR19 = CAR-T (NOT CRISPR). • ICMR Bioethics Unit = Bengaluru (NOT Delhi). • Casgevy (CRISPR sickle cell) = FDA approved Dec 2023 — US, not India.
Section 10
❓ FAQs — Concept Clarity
What is the difference between bioethics and medical ethics?
Medical ethics is the older, narrower field — it concerns the ethical obligations between a doctor and their patient. It covers clinical decision-making, professional conduct, informed consent in treatment, confidentiality, and end-of-life care. Bioethics is broader — it emerged in the 1970s as biological technologies advanced beyond the doctor's clinic. It covers not just clinical situations but also research ethics, environmental ethics of GM organisms, justice in global health, animal experimentation, genomics and data privacy, synthetic biology, and more. Bioethics is thus interdisciplinary (philosophy + biology + law + social sciences) where medical ethics is primarily within the healthcare profession. For UPSC GS-IV, the four principles of biomedical ethics bridge both fields.
Is CRISPR gene editing legal in India? What is India's regulatory position?
India does not have specific legislation on human gene editing. The applicable framework consists of: (1) EPA Rules 1989 — govern "Genetically Engineered Organisms or Cells," which technically include human cells; human germline editing would require RCGM and potentially GEAC oversight. (2) ICMR National Ethical Guidelines 2017 — require Institutional Ethics Committee approval for all research involving human participants; any clinical trial using gene editing would need IEC clearance and CDSCO drug approval. (3) New Drugs and Clinical Trials Rules 2019 (CDSCO) — regulate gene therapies as drugs/biologics. In practice, somatic cell gene therapies (like CAR-T) have been approved via CDSCO pathway. Germline editing in humans is not explicitly banned by statute in India — but no institutional approval would currently be given, and it would violate ICMR guidelines. India's March 2022 revision of EPA Rules exempted SDN-1 and SDN-2 gene-edited organisms (which don't introduce exogenous DNA) from GMO regulations for field trials — a significant progressive step for agricultural gene editing.
What is the Precautionary Principle and how does it apply to biotechnology in India?
The Precautionary Principle (Principle 15 of the Rio Declaration, 1992) states: where there are threats of serious or irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing protective measures. It places the burden of proof on the proponent of a new technology to demonstrate safety — not on regulators to prove harm. In biotechnology, it applies when: (1) GM crops could cause irreversible gene flow to wild relatives — used by India's Supreme Court to stay GM mustard commercial release; (2) Germline gene editing — permanent alteration of human inheritance justifies extreme caution even before full safety data exists; (3) Synthetic biology organisms released into the environment cannot be recalled. The Precautionary Principle must be balanced with the principle of proportionality — the level of caution should match the level of potential harm. Excessive precaution can also cause harm (e.g., blocking Bt brinjal that could benefit farmers in India, while it is safely used in Bangladesh).
What is biopiracy? How does India protect against it?
Biopiracy refers to the unauthorised appropriation of biological resources, traditional knowledge, or genetic resources — often by corporations or researchers from wealthy countries — without fair compensation or acknowledgement of the source communities. Famous examples: (1) Neem patent — W.R. Grace and the USDA patented neem fungicide properties in the US; India successfully challenged this at the European Patent Office — patent revoked in 2000. (2) Turmeric patent — University of Mississippi Medical Center patented turmeric's wound-healing properties; India's CSIR challenged it — patent revoked in 1997 by US Patent Office, citing traditional knowledge. India's protections: (1) Biological Diversity Act 2002 — National Biodiversity Authority (NBA) oversees ABS; foreign entities need NBA approval to access India's biological resources. (2) Nagoya Protocol 2010 ratified by India in 2014 — international ABS framework. (3) Traditional Knowledge Digital Library (TKDL) — database of 290,000+ traditional knowledge formulations in 5 languages, used as prior art to prevent biopiracy patents. (4) Patents Act Section 3(p) — prohibits patents on inventions that consist of aggregation or duplication of traditional knowledge.
How does bioethics connect to GS-IV (Ethics) for UPSC Mains?
Bioethics is a rich, concrete domain for applying GS-IV ethical frameworks. Here's how they map: (1) Consequentialism — GM crops that increase food production benefit many; gene therapy that cures rare disease benefits few but at enormous cost — the "greatest good for greatest number" calculation applies. (2) Deontology (Kant) — informed consent is a deontological requirement; using surrogates or trial subjects merely as means to others' ends violates the Categorical Imperative. (3) Virtue ethics — a virtuous scientist (like Hippocrates' ideal physician) would not conduct He Jiankui-style experiments driven by ambition rather than patient welfare. (4) Care ethics — bioethics must centre the relationships and vulnerabilities of the most affected (surrogates, trial participants, future generations of germline editing). (5) Environmental ethics — precautionary principle; rights of nature; intergenerational justice (obligations to future humans who will inherit a gene-edited world). For GS-IV answers, always link the bioethical issue to one of these frameworks with a concrete example — that's what distinguishes a good answer from a generic one.
Section 11
🏁 Conclusion — UPSC Synthesis
⚖️ Science Must Serve Humanity — Not The Other Way Around
Biotechnology stands at the most powerful threshold in human history — the ability to rewrite the code of life itself, cure diseases that have tormented humanity for millennia, and feed billions more from the same land. But He Jiankui's CRISPR babies remind us that the ability to act is not the same as the right to act. The twin girls born with edited genomes did not choose to be experiments. The communities whose DNA was collected for genomic databases did not always understand the commercial uses of their genetic information. The surrogate mothers who carried children for wealthy families did not always exercise free will when economic desperation made refusal impossible.
Bioethics is not about preventing progress — it is about ensuring that progress serves everyone, especially those who are most vulnerable and least powerful. India's bioeconomy at USD 165.7 billion (2024) and targeting USD 300 billion by 2030 is a story of extraordinary ambition. But sustainable bioeconomic growth requires ethical foundations: robust informed consent systems, genetic non-discrimination laws, accessible pricing for life-saving therapies like NexCAR19, legal recognition of all forms of families in reproductive technology policy, and ecological precaution in releasing GM organisms into India's irreplaceable biodiversity.
For UPSC Prelims: 4 principles = A-B-N-J (Beauchamp & Childress, 1979); Bioethics coined by Van Rensselaer Potter (1970); He Jiankui = CCR5 deletion, germline, 3 years prison, NOT Nobel; Genome India = DBT + IISc, 10,000 genomes, 99 groups, Jan 2020–2025, IBDC Faridabad; NexCAR19 = ImmunoACT (IIT Bombay), CDSCO Oct 2023, CAR-T, NOT CRISPR; Surrogacy Act 2021 = commercial ban, altruistic only; 3Rs (Russell & Burch) = Replace, Reduce, Refine; CPCSEA = animal ethics; ICMR Bioethics Unit = NCDIR Bengaluru; Precautionary Principle = Rio Declaration Principle 15; TKDL = prevents biopiracy.
For UPSC Mains: Frame every bioethics answer around the 4 principles. Use case studies. Link to GS-IV frameworks (Kantian deontology for consent, consequentialism for access justice). Connect to India-specific policies (ICMR guidelines, CDSCO, GEAC, Surrogacy Act). Always end with a constructive way forward — balancing innovation with ethical governance. Reference international instruments (Nuremberg, Helsinki, WHO 2021, Nagoya Protocol) where relevant.
